Serum biomarker analysis of collagen disease patients with acute-onset diffuseinterstitial lung disease

BMC Immunology

Shigeto Tohma²  Naoyuki Tsuchiya¹  Naoshi Fukui²  Hiromi Hayakawa²  Kota Shimada³  Hiroshi Furukawa²  Shomi Oka² 

[1] Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine,University of Tsukuba, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan;Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital,National Hospital Organization, 18-1 Sakuradai, Minami-ku, Sagamihara,Kanagawa, 252-0392, Japan;Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashi-dai, Fuchu, 183-8524,Japan

关键词: Interstitial lung disease;    Cytokine;    Biomarker;    Collagen disease;   

Others  :  1077837
DOI  :  10.1186/1471-2172-14-9

 received in 2012-10-30, accepted in 2013-02-01,  发布年份 2013

【 摘 要 】

Background

Interstitial lung disease (ILD) is frequently associated with collagen diseases. The prognosis of acute-onset diffuse ILD (AoDILD) occurring in collagen disease patients is very poor. Here, we investigated serum biomarker profiles of AoDILD to find markers predicting outcome in patients with collagen diseases.

Methods

A solid-phase antibody array was used for screening 274 biomarkers in pooled sera from collagen disease patients in the AoDILD state and in the stable state. Biomarkers in individual sera were detected without pooling by bead-based immunoassay.

Results

The serum levels of matrix metalloproteinase (MMP)-1, tissue inhibitor of metalloproteinase (TIMP)-1, osteopontin, interleukin (IL)-2 receptor α (IL-2Rα), and IL-1 receptor antagonist were significantly increased in AoDILD, but TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The MMP-3 to MMP-1 ratio was reduced in AoDILD state. This tendency was also observed in RA patients with AoDILD. Moreover, serum IL-6 level was significantly increased in the AoDILD state in patients with acute exacerbation of ILD (AE-ILD). Serum TIMP-1 and IL-2Rα levels were significantly increased in the AoDILD state in patients with drug-induced ILD (DI-ILD), whereas TIMP-2, MMP-3, and eotaxin 2 levels were decreased. The MMP-3 to MMP-1 ratio was reduced in AoDILD state in patients with DI-ILD. The serum TIMP-3, MMP-9, osteopontin, IL-2Rα, MMP-1, and MMP-8 levels were significantly increased in the AoDILD state in patients who subsequently died, whereas TIMP-2 and MMP-3 levels were decreased in those who survived. The MMP-3 to MMP-1 ratio was reduced in AoDILD state in patients who died, but not in those who survived.

Conclusions

Serum biomarker profiles could represent prognosis markers for AoDILD in collagen diseases.

【 授权许可】

   
2013 Oka et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Turesson C, Jacobsson LT: Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol 2004, 33:65-72.
• [2]Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, Dixey J, Gough A, Prouse P, Winfield J, et al.: Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology 2010, 49:1483-1489.
• [3]Kameda H, Tokuda H, Sakai F, Johkoh T, Mori S, Yoshida Y, Takayanagi N, Taki H, Hasegawa Y, Hatta K, et al.: Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011, 50:305-313.
• [4]Ricou B, Nicod L, Lacraz S, Welgus HG, Suter PM, Dayer JM: Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996, 154:346-352.
• [5]Suga M, Iyonaga K, Okamoto T, Gushima Y, Miyakawa H, Akaike T, Ando M: Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2000, 162:1949-1956.
• [6]Ohbayashi H: Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002, 3:409-421.
• [7]Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
• [8]Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581-590.
• [9]Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344-347.
• [10]Selman M, Ruiz V, Cabrera S, Segura L, Ramirez R, Barrios R, Pardo A: TIMP-1, -2, -3, and −4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am J Physiol Lung Cell Mol Physiol 2000, 279:L562-L574.
• [11]Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, Lindell KO, Cisneros J, Macdonald SD, Pardo A, et al.: MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008, 5:e93.
• [12]Fligiel SE, Standiford T, Fligiel HM, Tashkin D, Strieter RM, Warner RL, Johnson KJ, Varani J: Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 2006, 37:422-430.
• [13]Pardo A, Gibson K, Cisneros J, Richards TJ, Yang Y, Becerril C, Yousem S, Herrera I, Ruiz V, Selman M, et al.: Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005, 2:e251.
• [14]Kohan M, Puxeddu I, Reich R, Levi-Schaffer F, Berkman N: Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts. Ann Allergy Asthma Immunol 2010, 104:66-72.
• [15]Smith DR, Kunkel SL, Standiford TJ, Rolfe MW, Lynch JP 3rd, Arenberg DA, Wilke CA, Burdick MD, Martinez FJ, Hampton JN, et al.: Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Am J Respir Crit Care Med 1995, 151:1965-1973.
• [16]Vasakova M, Sterclova M, Kolesar L, Slavcev A, Pohunek P, Sulc J, Skibova J, Striz I: Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. Scand J Immunol 2009, 69:268-274.
• [17]Homolka J, Ziegenhagen MW, Gaede KI, Entzian P, Zissel G, Muller-Quernheim J: Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration 2003, 70:262-269.
• [18]Collard HR, Calfee CS, Wolters PJ, Song JW, Hong SB, Brady S, Ishizaka A, Jones KD, King TE Jr, Matthay MA, et al.: Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2010, 299:L3-L7.
• [19]Lewicki M, Kotyla P, Kucharz E: Increased adiponectin levels in women with rheumatoid arthritis after etanercept treatment. J Rheumatol 2009, 36:1346-1347.
• [20]Andersen GN, Nilsson K, Pourazar J, Hackett TL, Kazzam E, Blomberg A, Waldenstrom A, Warner J, Rantapaa-Dahlqvist S, Mincheva-Nilsson L, et al.: Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis. Respir Med 2007, 101:2199-2206.
• [21]Manetti M, Guiducci S, Romano E, Bellando-Randone S, Conforti ML, Ibba-Manneschi L, Matucci-Cerinic M: Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage. Ann Rheum Dis 2012, 71:1064-1072.
• [22]Oikonomidi S, Kostikas K, Tsilioni I, Tanou K, Gourgoulianis KI, Kiropoulos TS: Matrix metalloproteinases in respiratory diseases: from pathogenesis to potential clinical implications. Curr Med Chem 2009, 16:1214-1228.
• [23]Ahn JK, Koh EM, Cha HS, Lee YS, Kim J, Bae EK, Ahn KS: Role of hypoxia-inducible factor-1alpha in hypoxia-induced expressions of IL-8, MMP-1 and MMP-3 in rheumatoid fibroblast-like synoviocytes. Rheumatology (Oxford) 2008, 47:834-839.